SiBone (NASDAQ:SIBN – Get Free Report) Director Jeffrey Dunn sold 20,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $20.89, for a total value of $417,800.00. Following the completion of the sale, the director owned 16,057 shares in the company, valued at $335,430.73. This represents a 55.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
SiBone Stock Performance
Shares of NASDAQ SIBN opened at $24.95 on Thursday. The company has a current ratio of 9.15, a quick ratio of 7.55 and a debt-to-equity ratio of 0.20. SiBone has a 12 month low of $11.48 and a 12 month high of $25.92. The stock has a 50 day moving average of $19.61 and a 200-day moving average of $16.52. The company has a market capitalization of $1.11 billion, a P/E ratio of -80.48 and a beta of 0.64.
SiBone (NASDAQ:SIBN – Get Free Report) last posted its earnings results on Monday, November 2nd. The company reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.05. SiBone had a negative return on equity of 7.62% and a negative net margin of 6.20%. The business had revenue of $55.70 million for the quarter, compared to analyst estimates of $55.31 million. As a group, equities research analysts predict that SiBone will post -0.40 EPS for the current year.
Institutional Trading of SiBone
Several hedge funds and other institutional investors have recently bought and sold shares of SIBN. First Light Asset Management LLC boosted its stake in shares of SiBone by 51.8% in the second quarter. First Light Asset Management LLC now owns 8,127,985 shares of the company’s stock valued at $132,649,000 after buying an additional 2,774,795 shares during the period. Dimensional Fund Advisors LP grew its position in SiBone by 41.8% during the first quarter. Dimensional Fund Advisors LP now owns 618,939 shares of the company’s stock worth $7,816,000 after buying an additional 182,465 shares in the last quarter. Renaissance Technologies LLC grew its position in SiBone by 101.6% during the first quarter. Renaissance Technologies LLC now owns 472,619 shares of the company’s stock worth $5,969,000 after buying an additional 238,219 shares in the last quarter. Squarepoint Ops LLC increased its stake in SiBone by 40.3% during the 2nd quarter. Squarepoint Ops LLC now owns 118,128 shares of the company’s stock worth $1,928,000 after acquiring an additional 33,947 shares during the period. Finally, Granahan Investment Management LLC increased its stake in SiBone by 97.6% during the 1st quarter. Granahan Investment Management LLC now owns 1,739,097 shares of the company’s stock worth $21,965,000 after acquiring an additional 858,942 shares during the period. Institutional investors and hedge funds own 98.11% of the company’s stock.
Key Headlines Impacting SiBone
Here are the key news stories impacting SiBone this week:
- Positive Sentiment: Q3 results topped estimates. SiBone reported a loss of $0.08 per share, narrower than analysts’ expected $0.13 loss, and revenue of $55.7 million versus $55.3 million expected. Q3 earnings report
- Positive Sentiment: Analysts raised price targets and maintained Buy ratings. UBS lifted its target to $26 from $25, while TD Cowen raised its target to $23 from $20. These revisions indicate continued analyst support, although TD Cowen’s target is below the recent share price. UBS ratings TD Cowen ratings
- Neutral Sentiment: 2026 revenue guidance was reaffirmed. SiBone forecast full-year revenue of $231 million to $233 million, broadly in line with the $232.2 million consensus estimate, providing little change to expectations. Company Q3 results and guidance
- Negative Sentiment: Two insiders sold shares. Director Jeffrey W. Dunn sold 20,000 shares, cutting his stake by 55.47%; insider Anshul Maheshwari sold 3,738 shares. Insider selling can weigh on sentiment, though both retained shares after their transactions. Dunn SEC filing Maheshwari transaction details
Analysts Set New Price Targets
SIBN has been the topic of several research reports. Weiss Ratings raised SiBone from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 20th. Needham & Company LLC dropped their price target on SiBone from $27.00 to $26.00 and set a “buy” rating for the company in a report on Tuesday. TD Cowen boosted their price target on SiBone from $20.00 to $23.00 and gave the company a “buy” rating in a research note on Tuesday. Citigroup restated a “market outperform” rating on shares of SiBone in a research note on Tuesday. Finally, Truist Financial upped their price objective on SiBone from $23.00 to $25.00 and gave the company a “buy” rating in a report on Wednesday, October 14th. Seven research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, SiBone presently has an average rating of “Moderate Buy” and a consensus target price of $25.00.
Read Our Latest Research Report on SiBone
About SiBone
SI-BONE, Inc (NASDAQ: SIBN) is a medical device company focused on diagnosing and treating disorders of the sacroiliac joint, which connects the spine to the pelvis. The company develops minimally invasive surgical solutions intended to stabilize the sacroiliac joint and address sacroiliac joint dysfunction and related conditions.
Its product portfolio is centered on the iFuse Implant System, a family of triangular implants designed to be placed across the sacroiliac joint. SI-BONE also offers products such as iFuse-TORQ, a threaded implant system, and iFuse Bedrock Granite, which is designed for sacroiliac joint fusion and pelvic fixation as part of certain spinal procedures.
Featured Stories
- Five stocks we like better than SiBone
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
